Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients. Here, we investigated differences between age- and gender-normed body mass index-standardized z scores at baseline and after 8 weeks of open-label, flexible-dose risperidone treatment (mean dose: 1.70 mg/day) in 32 youths with pervasive developmental disorder (mean age = 8.74, range = 5-16 years) in relation to -759C/T 5-hydroxytryptamine 2C receptor (HTR2C) promoter and rs1414334 HTR2C intragenic C/G alleles, along with gender, age, and risperidone dose, using repeated measures analyses of variance. Carriers of the HTR2C promoter T allele gained an average of 0.043 ± 0.017 body mass index-standardized z scores (1.84 ± 1.51 kg) versus 0.64 ± 0.35 z (3.23 ± 1.47 kg) for non-T-allele carriers (p < 0.001). Presence of the rs1414334 C allele played no significant role. Further, weight gain appeared to be associated with younger age and higher doses of risperidone. The current preliminary findings suggest that the variant T allele of the -759C/T HTR2C promoter polymorphism is protective against risperidone-induced weight gain. Younger children and those treated with higher doses of risperidone may be at higher risk for weight gain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Self-citationFindling, R. L., Aman, M. G., Eerdekens, M., Derivan, A., Lyons, B., & The Risperidone Disruptive Behavior Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.677 · Cited by 161 · cited 2×
“However, weight gain is an important adverse effect of risperidone, particularly for children (Safer 2004), mean gains being in the range of 2.2–2.8 kg in the first 8 weeks of treatment in controlled studies (Findling et al. 2004; Shea et al. 2004; Troost et al. 2005; Fleischhaker et al. 2007).”
BackgroundInfluential
Cited by
Autism genetics: opportunities and challenges for clinical translation
Vorstman, J. A. S., Parr, J. R., Moreno-De-Luca, D., Anney, R. J. L., Nurnberger Jr, J. I., & Hallmayer, J. F. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.4 · Cited by 463
Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial
DeVane, C. L., Charles, J. M., Abramson, R. K., Williams, J. E., Carpenter, L. A., Raven, S., Gwynette, F., Stuck, C. A., Geesey, M. E., Bradley, C., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2271 · Cited by 60
Behavioral interventions for children with autism spectrum disorders
LeBlanc, L. A., & Gillis, J. M. (2012) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.10.006 · Cited by 48
Pharmacogenomic Medicine in Autism: Challenges and Opportunities
Bowers, K., Lin, P.-I., & Erickson, C. (2015) · Pediatric Drugs · doi:10.1007/s40272-014-0106-0 · Cited by 22
Metadata
- Authors
- Hoekstra, P. J., Troost, P. W., Lahuis, B. E., Mulder, H., Mulder, E. J., Franke, B., Buitelaar, J. K., Anderson, G. M., Scahill, L., & Minderaa, R. B.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2010-12
- Volume
- 20
- Issue
- 6
- Pages
- 473-477
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2037835401
- Cited by
- 51
- References
- 2
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.